We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+7.64%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.56B
AUM Growth
+$19.4M
Cap. Flow
-$249M
Cap. Flow %
-3.79%
Top 10 Hldgs %
37.22%
Holding
183
New
22
Increased
65
Reduced
79
Closed
14

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$38.5M
2
SAGE
Sage Therapeutics
SAGE
+$22M
3
SIBN icon
SI-BONE Inc
SIBN
+$19.1M
4
STE icon
Steris
STE
+$16.6M
5
CLDX icon
Celldex Therapeutics
CLDX
+$15.6M

Top Sells

Rank Stock Value
1
AXNX
Axonics, Inc. Common Stock
AXNX
+$114M
2
ISRG icon
Intuitive Surgical
ISRG
+$56.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$51.2M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$28.6M
5
EVH icon
Evolent Health
EVH
+$28.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.12%
2 Industrials 0.77%
3 Technology 0.02%
4 Communication Services 0.02%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RGNX icon
151
Regenxbio
RGNX
$623M
$253K ﹤0.01%
+12,000
New +$214K
MLTX icon
152
MoonLake Immunotherapeutics
MLTX
$1.59B
$221K ﹤0.01%
+4,400
New +$239K
BIDU icon
153
Baidu
BIDU
$35.8B
$211K ﹤0.01%
+2,000
New +$213K
AUTL
154
Autolus Therapeutics
AUTL
$386M
$207K ﹤0.01%
32,500
-17,500
-35% -$109K
BAX icon
155
Baxter International
BAX
$11.6B
$180K ﹤0.01%
+4,200
New +$171K
VTRS icon
156
Viatris
VTRS
$20.1B
$173K ﹤0.01%
14,515
-3,488
-19% -$42K
ETNB
157
DELISTED
89bio
ETNB
$159K ﹤0.01%
13,700
-6,500
-32% -$72K
IDYA icon
158
IDEAYA Biosciences
IDYA
$3.41B
$145K ﹤0.01%
+3,300
New +$142K
MLYS icon
159
Mineralys Therapeutics
MLYS
$2.35B
$119K ﹤0.01%
+9,200
New +$114K
NVDA icon
160
NVIDIA
NVDA
$5.01T
$87.6K ﹤0.01%
970
-20
-2% -$1.45K
QCOM icon
161
Qualcomm
QCOM
$176B
$87.5K ﹤0.01%
517
+170
+49% +$26.3K
ORCL icon
162
Oracle
ORCL
$331B
$85K ﹤0.01%
677
+223
+49% +$25.5K
A icon
163
Agilent Technologies
A
$39.1B
$78.6K ﹤0.01%
540
+177
+49% +$24.2K
MSFT icon
164
Microsoft
MSFT
$2.84T
$75.7K ﹤0.01%
180
+58
+48% +$23.5K
OABI icon
165
OmniAb
OABI
$294M
$62.1K ﹤0.01%
+11,456
New +$66K
MTD icon
166
Mettler-Toledo International
MTD
$26.8B
$43.9K ﹤0.01%
33
+8
+32% +$9.86K
LH icon
167
Labcorp
LH
$24.3B
$32.3K ﹤0.01%
148
-6,941
-98% -$1.53M
EXAI
168
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$15.1K ﹤0.01%
2,644
+879
+50% +$5.46K
IONQ icon
169
IonQ
IONQ
$12.3B
$11.1K ﹤0.01%
1,107
+366
+49% +$3.91K
DVA icon
170
DaVita
DVA
$15.1B
– –
-3,800
Closed -$398K
GDXJ icon
171
VanEck Junior Gold Miners ETF
GDXJ
$7.06B
– –
-5,000
Closed -$190K
KOS icon
172
Kosmos Energy
KOS
$1.56B
– –
-256,500
Closed -$1.72M
LTH icon
173
Life Time Group Holdings
LTH
$9.42B
– –
-25,200
Closed -$380K
LULU icon
174
lululemon athletica
LULU
$13B
– –
-770
Closed -$394K
MCHI icon
175
iShares MSCI China ETF
MCHI
$6.04B
– –
-4,100
Closed -$167K
4 5 6
7
8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q1 2024 Portfolio in Review

As of Q1 2024, Bellevue Group held 183 positions worth $6.56B, up 0.3% from $6.54B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Bellevue Group withdrew a net $249M in Q1 2024, closing 14 positions and reducing 79 holdings. Its most notable exit was Axonics, Inc. Common Stock, an estimated $114M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Industrials and Technology.

Against the trend, Bellevue Group opened a new position in Steris worth $16.5M.

  • Bellevue Group's largest Q1 2024 buy was Steris: 73,434 shares worth $16.5M.
  • Bellevue Group added most to DexCom in Q1 2024, an estimated $38.5M increase.
  • Bellevue Group's biggest Q1 2024 reduction was Intuitive Surgical, cutting an estimated $56.6M.
  • Bellevue Group fully exited Axonics, Inc. Common Stock in Q1 2024, selling an estimated $114M.
  • Bellevue Group's ten largest holdings make up 37% of its $6.56B portfolio in Q1 2024.
  • Bellevue Group opened 22 new positions and closed 14 in Q1 2024.
  • Bellevue Group's portfolio value rose 0.3% quarter-over-quarter to $6.56B.

Based on Bellevue Group's 13F filing for Q1 2024, filed 15 May 2024.